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Abstract 31	  
Monoclonal antibodies (MAbs) form a central part of chronic lymphocytic leukaemia (CLL) treatment. 32	  
We therefore evaluated whether complement defects in CLL patients reduced the induction of 33	  
complement-dependent cytoxicity (CDC), using anti-CD20 MAbs rituximab (RTX) and ofatumumab 34	  
(OFA). OFA elicited higher CDC levels than RTX in all CLL samples examined, particularly the poor 35	  
prognosis cohorts (11q- and 17p-). Serum sample analyses revealed 38.1% of patients were deficient 36	  
in one or more complement components, correlating with reduced CDC responses. While a proportion 37	  
of patients with deficient complement levels initially induced high levels of CDC, on secondary 38	  
challenge CDC activity in sera was significantly reduced, compared with normal human serum (NHS; 39	  
p<0.01; n=52). Additionally, high CLL cell number contributed to rapid complement exhaustion. 40	  
Supplementing CLL serum with NHS or individual complement components, particularly C2, restored 41	  
CDC on secondary challenge to NHS levels (p<0.0001; n=9). In vivo studies revealed that 42	  
complement components were exhausted in CLL patient sera post-RTX treatment, correlating with an 43	  
inability to elicit CDC. Supplementing MAb treatment with fresh frozen plasma may therefore maintain 44	  
CDC levels in CLL patients with a complement deficiency or high white blood cell count. This study 45	  
has important implications for CLL patients receiving anti-CD20 MAb therapy. 46	  
 47	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Introduction 51	  
Monoclonal antibody (MAb) therapies form an integral part of the treatment regime for chronic 52	  
lymphocytic leukaemia (CLL) patients. Current first line therapy involves administration of the purine 53	  
analogue fludarabine (F) and the DNA alkylating agent cyclophosphamide (C), in combination with 54	  
rituximab (RTX) a chimeric anti-CD20 MAb (FCR).1, 2 The biological activity of CD20, a B-cell marker, 55	  
is not fully elucidated, however it is thought to act as an ion channel and a store operated Ca2+ 56	  
channel.3, 4 As CD20 expression is restricted to the B-cell lineage, with no expression on stem cells or 57	  
mature plasma cells, it makes an ideal therapeutic target for B cell malignancies. The inclusion of 58	  
RTX to FC generated a radical improvement in progression free survival and response rates for CLL 59	  
patients.5 However despite these improvements relapse due to the re-emergence of minimal residual 60	  
disease still poses a problem for CLL patients,2, 6 especially those with adverse cytogenetics. Disease 61	  
progression through acquisition of chromosomal deletions/mutations in 17p/p53 is associated with 62	  
patients becoming refractory to fludarabine-based therapies, leaving few therapeutic options. These 63	  
patients can be treated with alemtuzumab an anti-CD52 MAb, with variable levels of response, 64	  
indicating that the clinical needs of this sub-set of CLL patients are still unmet by standard treatments. 65	  
A new generation type I, human immunoglobulin (Ig) G1k anti-CD20 MAb, ofatumumab (OFA), which 66	  
binds to a novel epitope of CD20,7 has been given FDA and EMEA approval for the treatment of 67	  
double refractory patients, refractory to both F and alemtuzumab. OFA has shown promising results 68	  
with >50% of CLL patients responding to treatment.7-9 69	  
MAbs exert anti-tumour activity by harnessing the body’s own natural immune response especially 70	  
antibody-dependent cellular cytotoxicity (ADCC) involving the recruitment of natural killer cells to 71	  
cause phagocytosis and complement-dependent cytotoxicity (CDC) requiring the activation of the 72	  
classical complement pathway, and/or apoptosis.10 Type 1 MAbs, such as RTX and OFA, localise 73	  
CD20 into lipid rafts enhancing C1q recruitment and activation of CDC.11 CDC induction is critically 74	  
dependent on the distance between MAb binding site and the plasma membrane, with closer binding 75	  
associated with more efficient coating of active complement components onto the target cell. Previous 76	  
studies have demonstrated that C1q binds more readily to OFA than RTX, with OFA also resulting in 77	  
more effective deposition of C3b onto the surface of the membrane, due to the novel epitope binding 78	  
site of OFA bringing the complex closer to the surface of the cell, thus increasing the amount of 79	  
CDC.11-14 This is of particular importance in CLL, as CD20 expression levels, which are relatively low 80	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compared to B-cell lymphomas, linearly correlate with the lytic response of RTX.15, 16 In addition, 81	  
recent studies demonstrate that CLL cells can evade RTX, through sequestration of CD20-RTX 82	  
complexes by phagocytic cells, resulting in trogocytosis. This enables CD20 depleted lymphocytes to 83	  
remain in circulation, no longer responsive to RTX treatment.17-19 These findings highlight the 84	  
importance of generating a MAb capable of effectively inducing CDC.  85	  
To maximise the clinical effect of MAbs, it is important to consider whether the patient will be able to 86	  
elicit CDC and ADCC responses to the drug.  Early reports indicated that CLL patients harbour 87	  
deficiencies in classical complement components C1 and C4 resulting in defective immune complex 88	  
clearance. Deficiencies in classical complement components have also been linked to CLL patients 89	  
being more susceptible to infections with organisms such as Streptococcus pneumonia, and 90	  
exhibiting a propensity to develop autoimmune syndromes.20-22 These findings raise two important 91	  
questions, first how frequently do complement deficiencies occur in CLL and second how does this 92	  
impact on the efficiency of MAb treatments? Here we demonstrate that 38.1% of our CLL patient 93	  
cohort harbour deficiencies or reduced levels in one or more complement components, significantly 94	  
impacting on their ability to elicit CDC response to OFA and RTX. Moreover, some patients that 95	  
initially induced a high level of CDC, display a significantly reduced CDC activity upon secondary 96	  
challenge in vitro and in vivo, indicating that rapid exhaustion of complement components occurs in 97	  
CLL patient serum, compared to normal donors. A high circulating CLL cell burden also contributes to 98	  
rapid complement exhaustion, in agreement with previously published work.23 Importantly we 99	  
establish that the reduction in CDC activity observed in CLL patient sera in vitro is overcome by 100	  
supplementing CLL serum with individual complement components or normal healthy serum (NHS) as 101	  
a source of complement. Collectively, our studies demonstrate that the majority of CLL patients have 102	  
sub-optimal levels of complement proteins/activity, a finding that has important implications for CLL 103	  
patients receiving MAb-based therapies.   104	  
 105	  
Materials and methods 106	  
Patient samples, CLL cell isolation and serum collection 107	  
Peripheral blood samples were obtained after informed consent, from patients with confirmed CLL 108	  
(Supplementary Table 1). Ethical approval for this study was obtained from the West of Scotland 109	  
Research Ethics Committee, NHS Greater Glasgow and Clyde (United Kingdom). CLL cells were 110	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isolated using RosetteSepTM human B cell enrichment cocktail (StemCell Technologies, Vancouver, 111	  
Canada) following the manufacturer’s instructions. CLL cell purity was >95%, determined by flow 112	  
cytometry (CLL: mean age 67.9 ± 6.78 years; range 48–88 years; percentage male 57.9%). 113	  
Peripheral blood samples were also collected from healthy volunteers to isolate normal healthy serum 114	  
(NHS; age range 25–50 years old) and age matched serum (AMS: mean age 64.8 ± 12.91 years; 115	  
range 47–84 years; percentage male 41.7%; Supplementary Table 2). Serum was separated from 116	  
freshly isolated blood collected using serum clot activator, by centrifugation at 3000g for 10 min. Sera 117	  
was immediately frozen on dry ice and stored at -80oC. Pooled NHS was prepared by mixing sera 118	  
from 10 different healthy volunteers, prior to freezing. 119	  
Cell culture and cell line conditions 120	  
CLL primary cells and the CLL cell line HG3 were cultured in RPMI-1640 containing 10% FBS, 50 121	  
U/mL penicillin, 50 mg/mL streptomycin and 2 mM L-glutamine (complete medium; Invitrogen Ltd., 122	  
Paisley, UK).  123	  
MAb treatment and assessment of cell death 124	  
Unless otherwise stated 2.5 x 106 cells/ml were pelleted by centrifuging for 5 min, 300g at room 125	  
temperature (RT), and then resuspended in CDC buffer - Hanks Buffered Saline Solution (HBSS; 126	  
PAA Laboratories, Austria), 10 mM Hepes, 1 mM sodium pyruvate and 10 µg/ml Gentamicin 127	  
(Invitrogen Ltd.). 20 mg/ml OFA (GlaxoSmithKline, UK) and 10 mg/ml RTX (Roche, UK) were diluted 128	  
in CDC buffer and added to cells at 20 µg/ml, for 30 min at RT. Untreated control cells were treated 129	  
equivalently except no MAb was added to the CDC buffer. CLL cells were then pelleted and the 130	  
supernatant removed. Thawed human serum was diluted in CDC buffer (1:1) and added to cells and 131	  
mixed gently. CLL cells were then incubated with sera for 2 hr at 37oC. Following MAb treatment, CLL 132	  
cells were washed in CDC buffer, harvested and stained with 1 µg/ml propidium iodide (PI) (BD 133	  
Biosciences, Oxford, UK). Following PI staining the percentage of CDC was determined by acquiring 134	  
flow cytometry data using a FACSCantoII flow cytometer (BD Biosciences). PI- cells were considered 135	  
viable. When patient sera were supplemented, purified human complement components C2 and/or 136	  
C4 (Complement Technology, Inc, Texas, USA) or NHS were added at the concentrations indicated. 137	  
Quantification of complement concentration and activity in sera 138	  
C1 and C2 levels in sera were determined by radial immunodiffusion (RID) (The Binding Site Group 139	  
Ltd., Birmingham, UK) following the manufacturer’s protocol. C3c and C4 were determined by 140	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immunonephelometry in the clinical diagnostic immunology laboratory (Gartnavel General Hospital, 141	  
NHS Greater Glasgow and Clyde). The activity of the classical complement cascade in serum was 142	  
determined using total haemolytic complement kit, CH100 assay (The Binding Site Group Ltd.) 143	  
following the manufacturer’s instructions. 144	  
Statistical analysis and Software 145	  
All statistical analysis was performed using GraphPad Prism 4 software (GraphPad Software Inc., 146	  
CA), P values were determined by students paired or unpaired t-test or mixed model Anova as 147	  
indicated. Mean ± standard error of mean (SEM) is shown. Flow cytometry data were acquired using 148	  
FACSDiva software (BD Biosciences) and analysed using FlowJo (Tree Star Inc., Ashland, OR) 149	  
software. 150	  
 151	  
Results 152	  
CLL patient sera display multiple deficiencies in components of the classical complement cascade. 153	  
Classical complement component levels (C1, C2, C3 and C4) were assessed in CLL patient sera and 154	  
sera from AMS controls. Patients displaying single deficiencies/reduced levels were noted in all 155	  
complement components screened (Figure 1A). In the AMS samples (n=12), complement deficiencies 156	  
slightly below normal range for C1, C2 and C3/C4 were observed in a minority of donors. Of the CLL 157	  
patients screened, 15.4% exhibited levels lower than the normal range of C1q in their sera (n=52) and 158	  
approximately 20% of patients displayed deficiencies in the levels of C2 and C4 (17.9%, n=56 and 159	  
20.6% n=63 respectively). Analysis of C3 levels revealed that 11.1% of patient sera (n=63) were 160	  
deficient in this component. Double deficiencies of C1/C4, C2/C4 and C3/C4 also occurred, at a 161	  
frequency of 3.2%, 3.2% and 4.8% respectively. Triple deficiency of C2/C3/C4 was seen in 3.2% of 162	  
CLL patients, and deficiency of C1q/C2/C3/C4 was observed in one patient within our cohort. In total 163	  
38.1% of CLL sera tested were deficient in at least one complement component (n=63). To determine 164	  
how this impacted on the sequential activation of the classical complement cascade in the CLL sera 165	  
we performed a CH100 assay. Surprisingly only 19.4% of CLL sera exhibited reduced complement 166	  
activity levels (Figure 1B), despite the high proportion displaying at least one component deficiency. 167	  
Complement deficiencies showed no correlation to prognostic markers, occurring at a similar 168	  
frequency in the different Binet stage, cytogenetic and ZAP-70 status groups for our CLL patient 169	  
cohort (Supplementary Figures 1-3).  170	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OFA induces higher levels of CDC than RTX. 171	  
CDC optimisation experiments were carried out on CLL cell lines to determine the optimal 172	  
concentration of RTX and OFA. Maximal cell kill occurred with 20 µg/ml OFA/RIT, and 50% sera (data 173	  
not shown). Using these conditions we determined whether levels of CDC varied between poor 174	  
prognosis patient cohorts. CDC was carried out on 15 patients, selected from three distinct 175	  
cytogenetic subgroups; 11q-, 17p- and normal/13q. As previously reported OFA demonstrated much 176	  
greater cell kill by CDC than RTX,12, 13 with 20 µg/mL eliciting high levels of cell death in all 177	  
cytogenetic groups (Figure 2A). Statistical analysis revealed that when compared to RTX, OFA 178	  
induced significantly more CDC-mediated cell death in 11q- and 17p- cohorts, with borderline 179	  
significant effect in normal/13q group (Figure 2B). As OFA induced high levels of cell kill it was 180	  
therefore used in all subsequent in vitro experiments. 181	  
CLL sera readily exhaust of complement activity following MAb therapy. 182	  
Our findings indicated that low levels of individual complement components observed in CLL patient 183	  
sera did not always directly impact on CH100 complement activity. We therefore hypothesised that 184	  
CLL patient serum might exhaust the available complement components more readily after eliciting a 185	  
CDC response. This is an important consideration given the repeated scheduling of MAbs in CLL. To 186	  
validate complement exhaustion OFA-mediated CDC was performed on the CLL cell line HG3 using 187	  
50% CLL patient sera, to approximate physiological conditions, with a NHS control included for 188	  
comparison. Following 2 hr incubation, cells were pelleted and CDC levels measured by PI staining. 189	  
The sera removed from this experiment was then re-used to promote a second CDC response on 190	  
OFA bound HG3 cells. Serum exhaustion was performed on 52 CLL patient sera and the difference in 191	  
CDC cell kill from the first to the second round of serum use was then plotted (Figure 3A and 192	  
Supplementary Figure 4), with representative data from three individual patient samples with poor 193	  
(CLL08), medium (CLL32) and good (CLL85) CDC activity shown (Figure 3B). Our results clearly 194	  
demonstrate that CLL patient sera show significantly more complement exhaustion compared to NHS 195	  
controls, with 42.3% of CLL patient sera showing more than 30% reduction in CDC activity from 196	  
primary to secondary use.  197	  
To determine whether CDC was affected by high tumour load, we carried out exhaustion assays 198	  
using NHS exposed to increasing numbers of primary CLL cells. The efficiency of CDC in primary 199	  
CLL cells did not decline significantly until 10000 cells/µl were present, at which point CDC activity 200	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dropped by 48.1% in the NHS from the primary use (Figure 3C). Given that CLL sera is more readily 201	  
depleted of complement activity than NHS, the CLL sera exhaustion assays carried out in Figure 3A & 202	  
B and in subsequent experiments were performed using 2500 cells/µl. These findings indicate that 203	  
tumour load will also have a significant negative impact on CDC activity.  204	  
CLL sera exhaustion can be reduced by the addition of a complement source. 205	  
To determine whether CDC could be improved in patients deficient in one or more complement 206	  
component, individual components were added back to CLL patient sera. Similar to a report by 207	  
Kennedy A.D., et al., we identified C2 as being the limiting factor.18 Upon addition of C2 to patient 208	  
sera we were able to abrogate complement exhaustion in three individual patients (Figure 4A). In a 209	  
larger patient cohort, supplementing the sera with C2 restored CDC cell kill from primary to secondary 210	  
sera use to levels observed for the NHS control (Figure 4B). In addition, the C2 concentration 211	  
displayed a significant negative correlation with sera exhaustion levels in CLL patients (Figure 4C; r2= 212	  
0.5260, p <0.0001). The levels of C4 also displayed a significant negative correlation with sera 213	  
exhaustion in CLL patients (Supplementary Figure 5), however only C2 alone or in combination with 214	  
C4 was able to augment CDC in deficient sera, supporting previous findings that C2 is the limiting 215	  
factor (Supplementary Figure 6). To determine whether we could protect against complement 216	  
consumption in a clinically-relevant manner, we added back 10% and 20% NHS (equivalent to fresh 217	  
frozen plasma (FFP) an available source of complement to CLL sera), prior to the first round of CDC. 218	  
Our results clearly demonstrate that adding back 20% NHS not only gave significant improvement to 219	  
the initial level of CDC but also decreased the amount of complement exhaustion on secondary use 220	  
(Figure 4D).  221	  
CLL sera exhaustion is observed in vivo. 222	  
Next we screened the sera of CLL patients undergoing RTX immunotherapy to establish whether 223	  
complement levels were severely diminished following RTX treatment in vivo. In addition in vitro CDC 224	  
assays were carried out using OFA treated HG3 cells, using the RTX treated patient sera. OFA was 225	  
chosen due to its ability to elicit higher levels of CDC in vitro than RTX, enabling a better range of 226	  
CDC response to be measured. Analysis 24 hr following RTX infusion revealed that only one CLL 227	  
patient serum sample (CLL108) demonstrated good CDC on OFA treated HG3 cells and no 228	  
complement exhaustion following RTX treatment, with additional patients displaying complement 229	  
levels falling below the expected normal range (Figure 5A), correlating with an inability to elicit a CDC 230	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response (Figure 5B). For the majority of patients 28 days was sufficient for complement levels to be 231	  
replenished following treatment, however this was not true for the patient already deficient in C2 232	  
(CLL106). Individual complement component levels also reflected how readily patient sera exhausted 233	  
following subsequent CDC challenge on OFA treated HG3 cells, with CLL106 displaying a marked 234	  
reduction in CDC cell kill in vitro prior to RTX infusion (Figure 5-Ci). This was more apparent post RTX 235	  
infusion with the majority of patients showing complete ablation of complement activity in vivo (Figure 236	  
5-Cii). These findings have important implications for the future management of CLL patients 237	  
receiving MAb therapy.  238	  
 239	  
Discussion 240	  
MAbs are now firmly established in the treatment of CLL, both first-line and in the relapse setting. 241	  
Type 1 anti-CD20 MAbs mediate their toxicity effects against CLL cells by using the patient’s natural 242	  
immune responses to induce cell death through ADCC and CDC. Previous reports have shown that 243	  
CDC is a finite process with complement becoming exhausted following MAb induced cell lysis.23 244	  
Earlier research indicated that around 50% of CLL patients are deficient in C1 and C4, key 245	  
components of the classical complement cascade, and this low complement activity is associated with 246	  
advanced disease and shorter survival time.20, 21, 24, 25 Despite these early reports there has been little 247	  
follow up to determine how these complement deficiencies influence the efficacy of MAb treatment, 248	  
with drugs such as OFA and RTX that are potent inducers of CDC.   249	  
CLL patients have lower classical complement levels 250	  
Our comprehensive assessment of the levels of all complement components involved in the first stage 251	  
of the classical cascade in CLL patient sera revealed that a high proportion of CLL patients harbour 252	  
deficiencies, with 38.1% displaying a reduced level of either in C1, C2, C3 or C4. Patients exhibited a 253	  
range of deficiencies from one to multiple complement components, with one individual demonstrating 254	  
a deficiency in all classical complement components examined. Levels of C1 and C3 were often 255	  
within the normal range, whereas subnormal levels of C2 (17.9% deficient) and C4 (20.6% deficient) 256	  
were more prevalent in the CLL patient cohort examined. We were unable to define any significant 257	  
differences in complement concentration within CLL patient clinical stage, poor prognostic 258	  
cytogenetics or ZAP-70 status (Supplementary Figure 1-3). C2 and C4 are both cleaved into two 259	  
fragments during classical complement activation, with C4b and C2a then forming a complex termed 260	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C3-convertase. C3-convertase is essential for cleaving C3, which enables the C3b fragment to 261	  
opsonise the target cell and act as a scaffold for the membrane attack complex to assemble so that 262	  
the target cell can be lysed. C3b also functions to opsonise bacteria strains, for clearance by the 263	  
classical pathway.10 CLL patients are frequently unable to effectively coat bacterial pathogens with 264	  
C3b, making them more susceptible to infection.22 Therefore these deficiencies could increase the 265	  
risk of life threatening infection, already a major concern in CLL patients.  266	  
CLL patient sera more readily exhaust complement, abrogating CDC activity 267	  
Although the high frequency of defects in complement levels did not correlate closely to overall 268	  
classical complement activity in vitro, analysis of patient sera revealed that significantly more CLL 269	  
patient sera samples underwent complement exhaustion on secondary challenge with bound MAb, 270	  
compared to the NHS controls (42.3%; n=52). In addition tumour burden impacted on CDC efficiency, 271	  
with high levels of sera exhaustion observed at medium-low tumour burden levels typically observed 272	  
for CLL, 1 x 104 CLL cells/µl. These findings are corroborated by Beurskens F.J. et al., who also 273	  
observed an elevated complement consumption with high cell counts. Moreover they demonstrated 274	  
that administering high concentrations of OFA did not substantially augment initial CDC induction, but 275	  
did affect the ability to induce a second round of CDC due to exaggerated complement activation and 276	  
consumption.23 Therefore any MAb treatments requiring CDC for potency will be limited by tumour 277	  
burden, and low complement component levels within CLL patient sera.  278	  
CDC activity can be restored in CLL patient sera with limited complement levels  279	  
Complement exhaustion has important implications for the dosing schedule of MAb treatment within 280	  
CLL as frequent dosing, which in addition to limiting the efficacy of the drug, will lead to sustained 281	  
complement exhaustion making patients more susceptible to infections. Having confirmed that C2 282	  
was depleted at a high frequency in CLL,18 we established that impaired CDC could be restored to a 283	  
normal NHS level by supplementing patient sera with C2. In addition, supplementing patient sera with 284	  
10 and 20% NHS was also sufficient to substantially improve OFA mediated CDC and enable 285	  
protection against complement exhaustion. Other studies suggest that RTX is not as effective at 286	  
depositing C3b onto the surface of cancer cells and is not as effective as OFA as a single agent in 287	  
CLL, yet it still showed significant improvement when administered together with FFP in a clinical trial 288	  
of fludarabine-refractory CLL patients, with minimal toxicity.2, 11, 26, 27 OFA is currently licensed for the 289	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treatment of double refractory patients and shows significant activity as a single agent, effectively 290	  
targeting CLL cells previously treated with RTX.7, 9 The improvement reported for the small cohort of 291	  
patients treated with RTX in combination with FFP, lend support for further investigation of MAb 292	  
therapy in combination with FFP infusions in clinical trials in the context of enhancing classical 293	  
complement pathway activity. This would be of particular importance for MAbs like OFA, which are 294	  
highly effective at using the complement system to induce cell death. Moreover, enhancement of CDC 295	  
by supplementing MAb therapy with FFP may also reduce the level of trogocytosis thus preventing 296	  
immune evasion of CLL cells. Indeed, our data highlight the importance of considering tumour burden 297	  
and patient complement levels prior to MAb therapy, as these factors could negatively impact on the 298	  
ability of the patient’s natural immune system to clear the malignant cells, thus reducing clinical 299	  
efficiency of the administered MAbs. Significantly, we demonstrate that complement exhaustion can 300	  
occur following RTX therapy in vivo, reducing both complement activity as shown previously,18 and 301	  
the serum concentrations of complement components, particularly C2 and C4. Analysis of sera from 302	  
CLL patients undergoing RTX immunotherapy, showed that 24 hr post RTX infusion, complement was 303	  
rapidly consumed by OFA treated HG3 cells, leading to a substantial decrease in CDC activity. 304	  
However in the majority of patients by day 28 CDC activity was restored, in line with complement 305	  
levels. Interestingly the patient whose CDC activity remained low at day 28 was deficient in C2, which 306	  
dropped even lower following RTX treatment and remained at low levels by day 28. We also observed 307	  
that sera from this patient exhausted readily in vitro, as was observed in vivo. In contrast to RTX, OFA 308	  
is typically administered as 8 weekly doses followed by 4 monthly treatments.7, 9 In a previous study, 309	  
patient complement levels were also reduced considerably following OFA infusion, especially after the 310	  
first infusion when CD20 levels were initially high.23 These findings have recently been confirmed by 311	  
Baig et al., who demonstrate that there is a rapid decrease in serum complement levels following OFA 312	  
treatment, which is sustained 24h post-treatment. In addition the CLL cells lose CD20 expression and 313	  
become insensitive to in vitro OFA-mediated CDC, whilst retaining their ability to undergo 314	  
alemtuzumab-mediated CDC when supplemented with 10% NHS.28  The greater dose-intensity, 315	  
coupled with the greater induction of CDC with OFA, suggests that sustained complement depletion is 316	  
more likely to occur during OFA treatment, in susceptible patients. In patients with complement 317	  
deficiencies, ineffective CDC may also result in non-lethal complement deposition on CLL cells, CD20 318	  
trogocytosis and subsequent resistance to OFA-mediated CDC. 319	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Conclusion 320	  
This study highlights that complement deficiencies are an important clinical issue in CLL and have 321	  
implications for the scheduling of MAb therapy, with repeated administration of MAb during treatment 322	  
likely to reduce clinical efficacy in CLL patients due to complement consumption and depletion leading 323	  
to an inability to elicit CDC. Indeed, our findings establish that physiological complement levels are 324	  
fundamental to maintaining clinical efficacy of current MAb regimes. Provision of FFP as a source of 325	  
complement in parallel with MAb therapy may provide a relatively simple and effective way to restore 326	  
complement levels to a normal range, enhance the clinical efficacy of the MAb therapy and possibly 327	  
reduce the risk of infection. This could ultimately result in improved response rates and progression 328	  
free survival. A clinical study to assess the impact of complement replenishment using FFP in CLL 329	  
patients receiving MAb therapy is clearly warranted. 330	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Figure legends 427	  
Figure 1. CLL patient sera exhibit deficiencies in key components of the classical complement 428	  
cascade and reduced complement activity. 429	  
A. The concentrations of complement components of the classical cascade were assessed. Mean of 430	  
individual patient samples and AMS controls is shown. NR: Normal Range. i. C1q levels were 431	  
determined by RID. NR was established from the manufacturer's guidelines (AMS, n=12; CLL sera, 432	  
n=52).  ii, C2 levels were determined by RID. NR was established from our AMS controls (AMS, 433	  
n=12; CLL sera, n=56). iii & iv. C3 & C4 concentrations respectively were determined by 434	  
immunonephelometry performed by the clinical diagnostic laboratory (AMS, n=12; CLL sera, n=63). 435	  
B. Activity of the classical complement cascade was measured using the CH100 assay in CLL sera 436	  
(n=62) and AMS control (n=12). CH100 units were determined against a standard curve following lytic 437	  
ring measurement produced by serum measured against a calibrator of known activity levels. An 438	  
unpaired t test revealed no significant difference in the mean complement levels and complement 439	  
activity when comparing AMS controls with CLL patient sera. 440	  
Figure 2. OFA induces greater cell kill through CDC than RTX.  441	  
A. CLL patient cells were treated with 20 µg/ml OFA or RTX and then incubated with 50% NHS and 442	  
the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead cells is 443	  
expressed relative to untreated control, graphs represent the mean ± S.D (n=5 for each patient 444	  
cohort). B. Statistical analysis using mixed model Anova following covariate adjustment of non-drug 445	  
control for OFA and RTX populations. 446	  
Figure 3. CLL patient sera exhausts more readily than NHS.  447	  
HG3 cells were treated with 20 µg/ml OFA and then incubated with 50% CLL patient sera or NHS and 448	  
the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead cells is 449	  
expressed relative to untreated control. A. CLL serum that caused ≥40% CDC in OFA treated HG3 450	  
cells in 1° use, was used again (2° use) and the percentage difference in CDC from 1° to 2° sera use 451	  
enabled calculation of exhaustion levels (n=52 CLL patient sera vs. n=12 individual NHS. p values 452	  
were determined by an unpaired t-test (** p<0.01). B. After induction of CDC from the first set of OFA-453	  
treated HG3 cells (1° use) sera were removed from the cells and used for a second time to determine 454	  
the CDC activity induced on fresh HG3 cells treated with 20 µg/ml OFA (2° use). Representative data 455	  
are shown from the sera of 3 CLL patients and NHS control. C. CLL primary cells (n=4 ± SEM) of 456	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different cell densities were treated with 20 µg/ml OFA. Sera were removed and re-challenged with 457	  
fresh CLL cells of matching cell density treated with 20 µg/ml OFA. CDC was measured at both 458	  
stages. p values were determined by a paired t-test (*, p<0.05). 459	  
Figure 4. CDC activity in complement deficient serum can be restored with the addition of 460	  
complement components.  461	  
C2 protects CLL patient sera against exhaustion.  CLL sera (n=9) that exhibited high levels of serum 462	  
exhaustion were supplemented with C2 (50 µg/ml), before being used to induce CDC in HG3 cells 463	  
treated with 20 µg/ml OFA (1° use). After the incubation period sera was removed and re-challenged 464	  
with HG3 cells treated with 20 µg/ml OFA (2° use). A. Representative results from 3 different CLL 465	  
patients are shown. B. Analysis of the percentage change in CDC from the 1° to 2° use,  p value was 466	  
obtained from a paired t-test (*** p<0.001) C. C2 levels in CLL patient sera were compared against 467	  
CLL patient sera exhaustion (n=47). Linear regression was applied to obtain values for r2, 0.5260 and 468	  
p value, <0.0001. D. 10 or 20% NHS was added to CLL sera (n=9 ± SEM) prior to CDC exhaustion, p 469	  
value was obtained from paired t test. (* p<0.05; ** p<0.01; *** p<0.001). Percentage of dead cells is 470	  
relative to untreated control.  471	  
Figure 5. Complement levels are exhausted in vivo. 472	  
Sera samples were collected from CLL patients undergoing RTX immunotherapy (concentration 473	  
shown in Supplementary Table 1). Sera were collected prior to RTX therapy (pre – RTX dose 1), 24 474	  
hr after treatment (post – RTX dose 1) and prior to the second dose of RTX, 28 days after dose 1 (pre 475	  
– RTX dose 2). A. The concentration of complement levels in CLL sera (n=6). i. C2 levels were 476	  
determined by RID. ii. & iii. C3 & C4 concentrations were determined by immunonophelometry. p 477	  
value was obtained from paired t test (* p<0.05; ** p<0.01). B. CDC was measured on HG3 cells 478	  
treated with 20 µg/ml OFA in 50% CLL sera (n=6). p value was obtained from paired t test (* p<0.05; 479	  
** p<0.01). C. Exhaustion was measured in sera collected i, prior to RTX therapy and ii, post – RTX 480	  
dose 1. After induction of CDC from the first set of OFA treated HG3 cells (1° use) sera were removed 481	  
from the cells and re-challenged with HG3 cells treated with 20 µg/ml OFA and CDC measured (2° 482	  
use). Percentage of dead cells is relative to untreated control. 483	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